Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128

Article  CAS  PubMed  Google Scholar 

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644–657

Article  CAS  PubMed  Google Scholar 

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347–357

Article  CAS  PubMed  Google Scholar 

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295–2306

Article  CAS  PubMed  Google Scholar 

Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [published correction appears in N Engl J Med 348(22):2271]. N Engl J Med 348(14):1309–1321

Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11–21

Article  CAS  PubMed  Google Scholar 

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341(10):709–717

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995–2008

Article  CAS  PubMed  Google Scholar 

Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413–1424

Article  CAS  PubMed  Google Scholar 

Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G et al (2020) SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 396(10254):819–829

Article  PubMed  Google Scholar 

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [published correction appears in Circulation. 2022 May 3;145(18):e1033] [published correction appears in Circulation. 2022 Sep 27;146(13):e185]. Circulation 145(18):e895–e1032

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM et al (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136(6):e137–e161

Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F et al (2020) Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet 396(10244):121–128

Article  CAS  PubMed  Google Scholar 

Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF et al (2022)  SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials [published correction appears in Lancet. 2023 Jan 14;401(10371):104]. Lancet 400(10354):757–767

Ferreira JP, Zannad F, Pocock SJ, Anker SD, Butler J, Filippatos G et al (2021) Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced. J Am Coll Cardiol 77(11):1397–1407

Article  CAS  PubMed  Google Scholar 

Shen L, Kristensen SL, Bengtsson O, Böhm M, de Boer RA, Docherty KF et al (2021) Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF. JACC Heart Fail 9(4):254–264

Article  PubMed  Google Scholar 

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700

Article  PubMed  PubMed Central  Google Scholar 

Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H et al (2013) Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94–8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 34(31):2453–2463

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tromp J, Ouwerkerk W, van Veldhuisen DJ, Hillege HL, Richards AM, van der Meer P et al (2022) A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction [published correction appears in JACC Heart Fail. 2022 Apr;10(4):295–296]. JACC Heart Fail 10(2):73–84

De Marzo V, Savarese G, Tricarico L, Hassan S, Iacoviello M, Porto I et al (2022) Network meta-analysis of medical therapy efficacy in more than 90,000 patients with heart failure and reduced ejection fraction. J Intern Med 292(2):333–349

Article  PubMed  PubMed Central  Google Scholar 

Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F et al (2014) Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 7(4):573–579

Article  CAS  PubMed  Google Scholar 

Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B et al (2012) Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol 60(20):2082–2089

Article  CAS  PubMed  Google Scholar 

Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ et al (2014) Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail 7(1):51–58

Article  CAS  PubMed  Google Scholar 

Arima S, Kohagura K, Xu HL, Sugawara A, Abe T, Satoh F et al (2003) Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 14(9):2255–2263

Article  CAS  PubMed  Google Scholar 

Lopaschuk GD, Verma S (2020) Mechanisms of cardiovascular benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: a state-of-the-art review. JACC Basic Transl Sci 5(6):632–644

Article  PubMed  PubMed Central  Google Scholar 

Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C et al (2020) Empagliflozin in heart failure: diuretic and cardiorenal effects. Circulation 142(11):1028–1039

Article  CAS  PubMed  PubMed Central  Google Scholar 

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al (2021) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [published correction appears in Eur Heart J. 2021 Oct 14]. Eur Heart J 42(36):3599–3726

Dekkers CCJ, Sjöström CD, Greasley PJ, Cain V, Boulton DW, Heerspink HJL (2019) Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. Diabetes Obes Metab 21(12):2667–2673

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A et al (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129(5):587–597

Article  CAS  PubMed  Google Scholar 

Eickhoff MK, Dekkers CCJ, Kramers BJ, Laverman GD, Frimodt-Møller M, Jørgensen NR et al (2019) Effects of dapagliflozin on volume status when added to renin-angiotensin system inhibitors. J Clin Med 8(6):779

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zanchi A, Burnier M, Muller ME, Ghajarzadeh-Wurzner A, Maillard M, Loncle N et al (2020) Acute and chronic effects of SGLT2 inhibitor empagliflozin on renal oxygenation and blood pressure control in nondiabetic normotensive subjects: a randomized, placebo-controlled trial. J Am Heart Assoc 9(13):e016173

Isshiki M, Sakuma I, Hayashino Y, Sumita T, Hara K, Takahashi K et al (2020) Effects of dapagliflozin on renin-angiotensin-aldosterone system under renin-angiotensin system inhibitor administration. Endocr J 67(11):1127–1138

Article  CAS  PubMed  Google Scholar